Researchers decipher when and why T cells become non-responsive to immunotherapy

By | October 30, 2021
Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are “exhausted” and have stopped working.